 ECOG performance status ≤ 1 (see Appendix A).  Prothombin time (PT) and partial thromboplastin time (PTT) within normal institutional limits. Patients with prolonged PTT determined to be due to lupus anticoagulant will not be excluded.  Patients must have adequate organ and marrow function as defined below: Absolute neutrophil count  1000/mcL Platelets  100,000/mcL Hemoglobin  10.0 g/dL Total bilirubin within normal institutional limits; in patients with Gilbert’s, ≤ 3.0 mg/dL AST (AGOT)/ALT (AGPT)  3X upper limit of normal. Creatinine within 1.5X upper limit of normal institutional limits  The effects of M7824, TriAd vaccines, and N-803 on the developing human fetus are unknown. For this reason, men and women of childbearing capacity must agree to use highly effective contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during the study and maintain such contraception until 2 months following the last dose of any study agent.